EP2857011A4 - PHARMACEUTICAL COMPOSITION FOR THE PROPHYLAXIS AND TREATMENT OF PSYCHOLOGICAL, BEHAVIORAL AND COGNITIVE DISORDERS - Google Patents

PHARMACEUTICAL COMPOSITION FOR THE PROPHYLAXIS AND TREATMENT OF PSYCHOLOGICAL, BEHAVIORAL AND COGNITIVE DISORDERS

Info

Publication number
EP2857011A4
EP2857011A4 EP12877152.4A EP12877152A EP2857011A4 EP 2857011 A4 EP2857011 A4 EP 2857011A4 EP 12877152 A EP12877152 A EP 12877152A EP 2857011 A4 EP2857011 A4 EP 2857011A4
Authority
EP
European Patent Office
Prior art keywords
psychic
cognitive
prevention
treatment
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12877152.4A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2857011A1 (en
Inventor
Margarita Alekseevna Morozova
Allan Gerovich Beniashvili
Maxim Eduardovich Zapolsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valenta Intellect LLC
Original Assignee
Valenta Intellect LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valenta Intellect LLC filed Critical Valenta Intellect LLC
Publication of EP2857011A1 publication Critical patent/EP2857011A1/en
Publication of EP2857011A4 publication Critical patent/EP2857011A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP12877152.4A 2012-05-24 2012-10-31 PHARMACEUTICAL COMPOSITION FOR THE PROPHYLAXIS AND TREATMENT OF PSYCHOLOGICAL, BEHAVIORAL AND COGNITIVE DISORDERS Withdrawn EP2857011A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2012121410/15A RU2488388C1 (ru) 2012-05-24 2012-05-24 Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
PCT/RU2012/000888 WO2013176567A1 (ru) 2012-05-24 2012-10-31 Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств

Publications (2)

Publication Number Publication Date
EP2857011A1 EP2857011A1 (en) 2015-04-08
EP2857011A4 true EP2857011A4 (en) 2015-12-02

Family

ID=49155569

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12877152.4A Withdrawn EP2857011A4 (en) 2012-05-24 2012-10-31 PHARMACEUTICAL COMPOSITION FOR THE PROPHYLAXIS AND TREATMENT OF PSYCHOLOGICAL, BEHAVIORAL AND COGNITIVE DISORDERS

Country Status (14)

Country Link
US (1) US20150157604A1 (esLanguage)
EP (1) EP2857011A4 (esLanguage)
JP (1) JP5864819B2 (esLanguage)
KR (1) KR101581611B1 (esLanguage)
CN (1) CN104334166A (esLanguage)
AU (1) AU2012380583B2 (esLanguage)
CA (1) CA2873891C (esLanguage)
EA (1) EA201400973A1 (esLanguage)
HK (1) HK1205467A1 (esLanguage)
IL (1) IL235852A0 (esLanguage)
IN (1) IN2014DN09940A (esLanguage)
RU (1) RU2488388C1 (esLanguage)
UA (1) UA112352C2 (esLanguage)
WO (1) WO2013176567A1 (esLanguage)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2536270C1 (ru) * 2013-10-21 2014-12-20 Общество с ограниченной ответственностью ООО "ВАЛЕНТА ИНТЕЛЛЕКТ" Комбинация для коррекции неврологического и психоэмоционального статуса при органических нарушениях цнс
DK3383482T3 (da) 2015-11-24 2023-04-11 Massachusetts Inst Technology Systemer og fremgangsmåder til forebyggelse, mildnelse og/eller behandling af demens
RU2623865C1 (ru) * 2016-06-29 2017-06-29 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция, содержащая комбинацию мемантина и мелатонина
RU2654713C1 (ru) * 2016-06-29 2018-05-22 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция, содержащая комбинацию мемантина и мелатонина
EP3479822B1 (en) * 2016-06-29 2023-06-07 Ltd. "Valenta-Intellekt" Pharmaceutical composition containing combination of memantine and melatonin
CN109922795B (zh) * 2016-10-31 2021-10-08 纽里姆药物有限公司 褪黑素小片剂及其制备方法
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
JP7082334B2 (ja) 2016-11-17 2022-06-08 コグニート セラピューティクス,インク. 視覚刺激を介した神経刺激のための方法およびシステム
US10960225B2 (en) * 2017-10-10 2021-03-30 Massachusetts Institute Of Technology Systems and methods for preventing, mitigating, and/or treating dementia via visual stimulation that binds higher order brain regions, reduces neurodegeneration and neuroinflammation, and improves cognitive function
CN111565698A (zh) 2017-10-10 2020-08-21 麻省理工学院 用于预防、减轻和/或治疗痴呆的系统和方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006009769A1 (en) * 2004-06-17 2006-01-26 Forest Laboratories, Inc. Modified release formulation of memantine
WO2008005534A2 (en) * 2006-07-06 2008-01-10 Forest Laboratories, Inc. Orally dissolving formulations of memantine

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7305644A (esLanguage) 1972-04-20 1973-10-23
DE2856393C2 (de) 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
EP0392059B1 (de) 1989-04-14 1993-09-15 Merz & Co. GmbH & Co. Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie
US5614560A (en) 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US6469044B1 (en) 1995-02-01 2002-10-22 Neurim Pharmaceuticals (1991) Ltd. Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
CA2292558C (en) * 1997-06-30 2006-09-19 Merz + Co. Gmbh & Co. 1-amino-alkylcyclohexane nmda receptor antagonists
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US20050129783A1 (en) * 2001-04-19 2005-06-16 Mccleary Edward L. Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health
US7183321B2 (en) * 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
DK1562585T3 (da) 2002-10-30 2011-03-14 Asat Ag Applied Science & Tech Daglige melatonindoseringsenheder
RU2268737C2 (ru) 2004-02-16 2006-01-27 Государственное учреждение институт клинической иммунологии СО РАМН Способ лечения атопического дерматита
EP1841460A2 (en) * 2004-06-18 2007-10-10 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
CN101374525A (zh) * 2004-09-23 2009-02-25 莫茨药物股份两合公司 美金刚治疗儿童行为障碍
MY148806A (en) * 2005-04-04 2013-05-31 Takeda Pharmaceutical Prophylactic or therapeutic agent for nocturnal conduct disorder associated with dementia
CN1709230A (zh) * 2005-07-05 2005-12-21 北京阜康仁生物制药科技有限公司 盐酸美金刚分散片及其制备方法
RU2294741C1 (ru) 2005-08-08 2007-03-10 Рина Михайловна Заславская Способ лечения больных ишемической болезнью сердца, стабильной стенокардией в сочетании с артериальной гипертонией
KR20090024140A (ko) * 2006-05-22 2009-03-06 반다 파마슈티칼즈, 인코퍼레이티드. 우울증 질환에 대한 치료
MX2008014843A (es) * 2006-05-22 2008-12-05 Vanda Pharmaceuticals Inc Tratamiento de trastornos depresivos.
CA2654523A1 (en) * 2006-07-05 2008-01-10 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions of memantine
GB0623897D0 (en) * 2006-11-30 2007-01-10 Pliva Istrazivanje I Razvoj D Pharmaceutical composition of memantine
US20080167363A1 (en) * 2006-12-28 2008-07-10 Braincells, Inc Modulation of Neurogenesis By Melatoninergic Agents
RU2326660C1 (ru) 2007-03-14 2008-06-20 Закрытое акционерное общество "Биологические исследования и системы" Пероральный лекарственный препарат мемантин (варианты) и способ его получения (варианты)
AU2008239683B2 (en) 2007-04-11 2014-03-27 Pharmaceuticals Productions Inc Melatonin tablet and methods of preparation and use
BRPI0811052A2 (pt) 2007-04-12 2015-01-27 Univ Minnesota Composições de proteção de isquemia/reperfusão e métodos de uso.
US20100256184A1 (en) * 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
CA2751667C (en) * 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
RU2394571C1 (ru) 2009-05-14 2010-07-20 Государственное бюджетное учреждение здравоохранения города Москвы "Городская клиническая больница № 24" Департамента здравоохранения города Москвы Способ лечения воспалительных заболеваний кишечника
RU2418586C2 (ru) 2009-06-11 2011-05-20 Государственное образовательное учреждение высшего профессионального образования "Новосибирский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО НГМУ Росздрава) Способ коррекции нарушений в репродуктивных органах, вызванных высокой температурой
RU2428183C1 (ru) 2010-07-01 2011-09-10 Рина Михайловна Заславская Адаптоген для метеочувствительных больных стенокардией и артериальной гипертензией и применение мелатонина в качестве адаптогена

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006009769A1 (en) * 2004-06-17 2006-01-26 Forest Laboratories, Inc. Modified release formulation of memantine
WO2008005534A2 (en) * 2006-07-06 2008-01-10 Forest Laboratories, Inc. Orally dissolving formulations of memantine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LAHIRI ET AL: "Amyloid, cholinesterase, melatonin and metals and their roles in aging and neurodegenerative diseases", ANN. N.Y. ACAD SCI., vol. 1956, 2005 - 2005, pages 430 - 449, XP002747443 *
LEWY ET AL: "Melatoinin treatment of winter depression; a pilot study.", RSYCHIATRY RES., vol. 77, 1998 - 1998, pages 57 - 61, XP002747444 *
See also references of WO2013176567A1 *

Also Published As

Publication number Publication date
US20150157604A1 (en) 2015-06-11
JP2015517569A (ja) 2015-06-22
JP5864819B2 (ja) 2016-02-17
CN104334166A (zh) 2015-02-04
WO2013176567A1 (ru) 2013-11-28
CA2873891C (en) 2016-02-16
IL235852A0 (en) 2015-01-29
EP2857011A1 (en) 2015-04-08
EA201400973A1 (ru) 2015-02-27
IN2014DN09940A (esLanguage) 2015-08-14
UA112352C2 (uk) 2016-08-25
AU2012380583B2 (en) 2015-01-22
AU2012380583A1 (en) 2014-12-18
KR20150005999A (ko) 2015-01-15
KR101581611B1 (ko) 2015-12-31
RU2488388C1 (ru) 2013-07-27
CA2873891A1 (en) 2013-11-28
HK1205467A1 (en) 2015-12-18

Similar Documents

Publication Publication Date Title
EP2857011A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PROPHYLAXIS AND TREATMENT OF PSYCHOLOGICAL, BEHAVIORAL AND COGNITIVE DISORDERS
EP2740489A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF PANCREATIC CARCINOMA
EP2838549A4 (en) MEDICINAL PRODUCT FOR THE PREVENTION OR TREATMENT OF NON-ALCOHOLIC FAT TEMPERATURE DISEASE
EP2818482A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
EP2818481A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
EP2824114A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
EP2832366A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF GAD BUBBLE
EP2532367A4 (en) PHARMACEUTICAL AGENT FOR THE TREATMENT AND / OR PREVENTION OF CANCER
EP2818483A4 (en) MEDICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER
EP2812004A4 (en) COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCLE ATROPHY
EP2532743A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
EP2532364A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER
EP2914277A4 (en) ACTIVIN ACTRII ANTAGONISTS AND USES FOR THE TREATMENT OF BONE AND OTHER DISEASES
EP2651496A4 (en) DEVICES, SYSTEMS AND METHODS OF TREATING MEDICAL DISEASES
EP2786758A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING COGNITIVE DISORDER WITH SPINOSYN
EP2601951A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF HEMORRH HORSES CAUSED BY BLOOD GRANULAR MATERIALS
EP2849738A4 (en) HIGH-POWDER PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF LUNG DISEASES
FR3032353B1 (fr) Composition pharmaceutique et dispositif pour le traitement de la douleur
EP3672587A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES
EP2857037A4 (en) MEANS FOR THE PREVENTION AND / OR TREATMENT OF PERIPHERAL NEUROPATHIC PAIN BY ANTICROBIAL AGENTS
MA45226A (fr) Compositions et méthodes de traitement ou de prévention d'affections liées à l'oxalate
KR102228571B9 (ko) 정신질환 또는 중추신경계 질환 치료용 약물전달 제형
BR112014025339A2 (pt) Método para tratamento ou prevenção ou redução de infecção do virus influenza e composição farmacêutica para o mesmo
EP2857007A4 (en) PHARMACEUTICAL COMPOSITION WITH VERBENON DERIVATIVES FOR TREATING OR PREVENTING NEURODEGENATIVE ILLNESSES
EP2611437A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING AMYOTROPHER LATERAL SCLEROSIS

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20141029

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/4045 20060101ALI20151022BHEP

Ipc: A61P 25/00 20060101ALI20151022BHEP

Ipc: A61K 31/13 20060101AFI20151022BHEP

Ipc: A61K 9/20 20060101ALI20151022BHEP

Ipc: A61K 9/48 20060101ALI20151022BHEP

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20151030

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

INTG Intention to grant announced

Effective date: 20160805

18W Application withdrawn

Effective date: 20160815